InnoCare Pharma Ltd (9969.HK) - Risk of Becoming Mediocre
This article analyzed InnoCare in terms of its core product orelabrutinib, key product candidates in the pipeline, the competitive landscape, the...
239 Views
Asia Ex-Japan Positioning: India & Tech at Record Highs
In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.
179 Views
China Healthcare Weekly (Sep.3) - Price Reform of Medical Services, Medical Beauty, Functional Food
This article mainly analyzed the pilot plan for the price reform of medical services, new regulation on medical beauty advertisement, functional...
209 Views
Jiangsu Hengrui Medicine (600276.CH) - The Concerns and the Outlook
The article analyzed Hengrui in terms of its 2021/1H performance, pipeline, key products, industry policy impact, innovation trend, development...
281 Views
Innovent Biologics (1801.HK) - The Strength and the Concerns
This article analyzed Innovent about 2021H1 performance, commercialized products, pipeline, concerns of the Company, and also include thoughts on...
203 Views